Special Issue

Michael J. Bonios

Adjunct Instructor of Cardiology, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Utah, USA

About the Guest Editor:

Michael J. Bonios (Adjunct Instructor of Cardiology, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Utah, USA)

Doctoral (PhD) Thesis (2003-2007): Title: “IABP augments coronary blood flow in a pig ischemia– reperfusion model”, University of Athens School of Medicine ‘Alexandra Hospital’, Athens, Greece (Mentor: Prof. John N. Nanas)

Licenses and certification (2015-2016): Physician Educator type II licensure, State of Utah Medical Associations (2020): Member, Heart Failure Association of the European Society of Cardiology, Committee on Advanced Heart Failure/ MCS / Transplant

Awards (2022): Best abstract award, 22^th Panhellenic Heart Failure Conference, Athens, Greece

About the Special Issue:

Heart failure and cardiovascular disease (CVD) remain major health challenges worldwide. However, recent advances in medical research have brought about new therapies for heart failure and innovative treatments for CVD. This special issue will provide a comprehensive overview of the latest developments in these areas. One of the main topics covered in this special issue is new therapies for heart failure. Heart failure is a condition in which the heart cannot pump blood effectively, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. Recent research has shown promising results in the development of new therapies for heart failure, such as gene therapy and stem cell therapy. These therapies aim to repair damaged heart tissue and improve the heart's ability to pump blood, ultimately improving the quality of life for heart failure patients. In addition, this special issue will cover advances in CVD treatment. CVD is a group of disorders that affect the heart and blood vessels, including coronary artery disease, heart attacks, and stroke. In recent years, there have been significant advances in the prevention and treatment of CVD, including new drugs and procedures for managing cholesterol, hypertension, and arrhythmias. Moreover, the emergence of digital health technologies has enabled more personalized and effective management of CVD, such as remote monitoring and mobile health apps.

This special issue will bring together leading experts in the field to share their knowledge and insights into the latest therapies and treatments for heart failure and CVD. It will feature original research articles, review papers, and case studies, providing a wealth of information for clinicians, researchers, and healthcare professionals. By presenting the latest advancements in the field, this special issue aims to improve patient outcomes and ultimately contribute to the reduction of cardiovascular disease worldwide.

Interventional Cardiology is going to accept the articles for the upcoming special issue:

The special issue "New Therapies for Heart Failure and Advances in Cardiovascular Disease Treatment" will cover a wide range of topics related to heart failure and cardiovascular disease (CVD) treatment. Here are some examples of the types of articles that may be included in the issue:

1. Original research articles on new therapies for heart failure, such as gene therapy and stem cell therapy, and their effectiveness in improving heart function and patient outcomes.
2. Review articles on advances in CVD treatment, including new drugs and procedures for managing cholesterol, hypertension, and arrhythmias, as well as the use of digital health technologies for personalized management.
3. Case studies of heart failure patients who have undergone innovative therapies or treatments, including their clinical outcomes and quality of life improvements.
4. Mini reviews/Commentaries or perspectives on the current state of heart failure and CVD treatment and the future direction of research and clinical practice in these fields.
5. Articles on the latest developments in CVD prevention, including risk assessment tools and lifestyle interventions for reducing the risk of CVD.